Update
$TriSalus Life Sciences (TLSI.US)$ Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications Via BusinessWire TLSI Share – New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal melanoma, consistent with an earlier presentation from pancreatic adenocarcinoma trial – – Median Progression-Free Survival was 11.7 months, with an 81% Disease Control Rate with the optimal biologic dose of SD-101 (2 mg) in combination with nivolumab –![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
JESSE JAMES8832 : on top of it as usual my friend![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP JESSE JAMES8832 : Thank you! Hope you’re having a great weekend![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")